KRAS and CREBBP mutations: a relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia

K Malinowska-Ozdowy, Christian Frech, Andreas Schönegger(CeMM Research Center for Molecular Medicine), Cornelia Eckert(Charité - Universitätsmedizin Berlin), Giovanni Cazzaniga(University of Milano-Bicocca), Martin Stanulla(Medizinische Hochschule Hannover), Udo zur Stadt(Universität Hamburg), A Mecklenbräuker, Michael Schuster(CeMM Research Center for Molecular Medicine), Doris Kneidinger, Arend von Stackelberg(Charité - Universitätsmedizin Berlin), Franco Locatelli(Bambino Gesù Children's Hospital), Martin Schrappe(University Hospital Schleswig-Holstein), Martin A. Horstmann(Universität Hamburg), Andishe Attarbaschi(St Anna Children's Hospital), Christoph Bock(CeMM Research Center for Molecular Medicine), Georg Mann(St Anna Children's Hospital), Oskar A. Haas(St Anna Children's Hospital), R Panzer-Grümayer
Leukemia
April 28, 2015
Cited by 125Open Access
Full Text

Abstract

High hyperdiploidy defines the largest genetic entity of childhood acute lymphoblastic leukemia (ALL). Despite its relatively low recurrence risk, this subgroup generates a high proportion of relapses. The cause and origin of these relapses remains obscure. We therefore explored the mutational landscape in high hyperdiploid (HD) ALL with whole-exome (n=19) and subsequent targeted deep sequencing of 60 genes in 100 relapsing and 51 non-relapsing cases. We identified multiple clones at diagnosis that were primarily defined by a variety of mutations in receptor tyrosine kinase (RTK)/Ras pathway and chromatin-modifying genes. The relapse clones consisted of reappearing as well as new mutations, and overall contained more mutations. Although RTK/Ras pathway mutations were similarly frequent between diagnosis and relapse, both intergenic and intragenic heterogeneity was essentially lost at relapse. CREBBP mutations, however, increased from initially 18-30% at relapse, then commonly co-occurred with KRAS mutations (P<0.001) and these relapses appeared primarily early (P=0.012). Our results confirm the exceptional susceptibility of HD ALL to RTK/Ras pathway and CREBBP mutations, but, more importantly, suggest that mutant KRAS and CREBBP might cooperate and equip cells with the necessary capacity to evolve into a relapse-generating clone.


Related Papers

No related papers found

Powered by citation graph analysis